Victoria Wurcel

Victoria is a medical specialist in Family & Preventive Medicine. She holds a Master’s degree in Clinical Effectiveness and has Postgraduate Diplomas in HTA and Economic Evaluation in Health.

Over the past seven years, Victoria has built experience in HTA management in the public sector of Argentina, including assessments of in vitro diagnostics and medical devices and hospital-based HTA. Victoria also coordinated the local UCEETS government HTA Network and represented Argentina in Int’l HTA Networks including INAHTA.

She has experience in Clinical Trial Design & Management and data monitoring. Quality Assurance and Patient Safety have been a key focus of her work for the public sector.

She has a Polish and Argentine citizenship. She speaks English and Spanish and is proficient in French and Portuguese.

 

Editors’ Note: This blog is part 2 of a series on VODI, the Value of Diagnostics Information initiative which aims at providing tools to demonstrate and communicate the value of diagnostic information to payers and patients. For part 1 of this series click here . During the European MedTech Forum (2-4 December 2015) follow the conversation and learn from industry experts using the Twitter hashtag #mtf2015 In vitro diagnostics (IVDs) allow users to make informed decisions on the best way to treat patients. Based on information from blood, urine or tissue samples, IVDs can help to select the right treatment option and, in some cases, avoid unnecessary interventions. IVDs have developed rapidly in Europe, primarily focusing in the needs of the laboratory and pathology setting. Through the information they give, innovative IVDs offer high-quality, accurate and rapid diagnosis; provide multiple testing technologies on a single instrument; and offer efficient automation of samples. This efficiency at the health care institution level has undoubtedly increased the overall value of IVDs. But the way in which decisions are made is changing. IVD manufacturers – 95% of which are SMEs – are increasingly asked for evidence of other dimensions of the value their products bring. These questions come not just from those who use IVDs in labs but from HTA assessors, insurers and other decision-makers, as well as healthcare providers and patients. The challenge for manufacturers is that different European health systems demand different data. The criteria used by HTA authorities in one country differ from those used by their neighbour and are not linked to decisions on funding, reimbursement or use for IVDs. At the same time, few reimbursement or uptake decisions are made based on value – reimbursement is generally based on lump sums for healthcare institutions and labs, with prize being...